Axogen Announces Merger to Acquire BioCircuit for $200M

What Happened
Axogen, Inc. (AXGN) filed an 8‑K reporting that on September 9, 2026 it entered into an Agreement and Plan of Merger to acquire BioCircuit Technologies, Inc. for a base purchase price of $200.0 million in cash. The Merger Sub will merge into BioCircuit, which will become a wholly owned subsidiary of Axogen. The company expects to close the Merger in Q4 2026, subject to customary closing conditions. On September 10, 2026 Axogen also entered an underwriting agreement to sell 4,910,000 shares of common stock in a public offering priced at $42.50 per share (underwriters’ purchase price $39.95), with a 30‑day option for up to 736,500 additional shares.

Key Details

• Merger price: $200.0 million cash base consideration; $1.0 million to be withheld at closing for post‑closing purchase price adjustments.
• Timing & conditions: Parties expect closing in Q4 2026; closing conditions include consent under an inbound IP license, conversion of BioCircuit convertible notes to equity, and a spin‑out of an unrelated electronics business. Merger agreement signed Sept 9, 2026.
• Financing: Axogen intends to fund the Merger with net proceeds from the public offering; company must obtain sufficient funding within 90 days of the Merger Agreement (failure to do so is a breach). The offering is expected to close Sept 11, 2026.
• Other: Representations and warranties do not survive closing; Axogen obtained representation and warranty insurance. Underwriters: BofA Securities, Jefferies and Wells Fargo. Legal opinion from Blue Chip Law, PLLC filed.

Why It Matters
The transaction would add BioCircuit’s peripheral nerve repair products (NerveTape and ConformaWrap) to Axogen’s portfolio, potentially expanding its clinical product offerings. For investors, the filing ties the acquisition closely to a sizable equity offering, which may dilute existing shareholders but provides the company the cash to complete the deal. The Merger remains subject to conditions and could fail or be delayed; Axogen highlights integration and realization of benefits as material risks.